Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor

Virology

Volumn 244, Issue 2, 1998, Pages 302-314

  Martino, Tami A ^a,c   Petric, Martin ^b,c   Brown, Martha ^c   Aitken, Karen ^a   Gauntt, Charles J ^d   Richardson, Christopher D ^e   Chow, Lawrence H ^f   Liu, Peter P ^a,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e AMGEN INC   (United States)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR;

ARTICLE; CARDIOTOXICITY; CARDIOVIRUS; CELL DEATH; COXSACKIE VIRUS; DRUG RECEPTOR BINDING; HEART DISEASE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MYOCARDITIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; VIRUS STRAIN; VIRUS VIRULENCE;

ADENOVIRIDAE; CARDIOVIRUS; COXSACKIEVIRUS; HUMAN ADENOVIRUS TYPE 2; RNA VIRUSES;

EID: 0032503216     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9122     Document Type: Article

References (53)

1. Aretz H. T. Myocarditis: The Dallas criteria. Hum. Pathol. 18:1987;619-624.
2. Aretz H. T., Billingham M. E., Edwards W. D., Factor S. M., Fallon J. T., Fenoglio J. J. Jr., Olsen E. G. J., Schoen F. J. Myocarditis: A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1:1987;3-14.
3. Bergelson J. M., Chan M., Solomon K. R., St. John N. F., Lin H., Finberg R. W. Decay-accelerating factor (CD55), a glycosylphosphatidyl-inositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. USA. 91:1994;6245-6249.
4. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997a;1320-1323.
5. Bergelson J. M., Modlin J. F., Wieland-Alter W., Cunningham J. A., Crowell R. L., Finberg R. W. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J. Infect. Dis. 175:1997b;697-700.
6. Bergelson J. M., Mohanty J. G., Crowell R. L., St. John N. F., Lublin D. M., Finberg R. W. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J. Virol. 69:1995;1903-1906.
7. Carson S. D., Chapman N. M., Tracy S. M. Purification of the putative coxsackievirus B receptor from HeLa cells. Biochem. Biophys. Res. Commun. 233:1997;325-328.
8. Chapman N. M., Tu Z., Tracy S., Gauntt C. J. An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: Its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses. Arch. Virol. 135:1994;115-130.
9. Chow L. H., Gauntt C. J., McManus B. M. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice: A pathologic characterization of heart tissue damage. Lab. Invest. 64:1991;55-64.
10. Coyne K. E., Hall S. E., Thompson E. S., Arce M. A., Kinoshita T., Fujita T., Anstee D. J., Rosse W., Lublin D. M. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149:1992;2906-2913.
11. Crowell R. L. Comparative generic characteristics of picornavirus-receptor interactions. Cell Membrane Receptors for Viruses, Antigens and Antibodies, Polypeptide Hormones and Small Molecules. 1976;Raven Press, New York. p. 179-202.
12. Davis L. S., Patel S. S., Atkinson J. P., Lipsky P. E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J. Immunol. 141:1988;2246-2252.
13. Davitz M. A., Low M. G., Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PlPLC). Selective modification of a complement regulatory protein. J. Exp. Med. 163:1986;1150-1161.
14. Gauntt C. J., Gomey P. T., Duffey P. S., Grant J. A., Trent D. W., Witherspoon S. M., Paque R. E. Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected murine strains. J. Virol. 52:1984;598-605.
15. Greve J. M., Davis G., Meyer A. M., Forte C. P., Yost S. C., Marlor C. W., Kamarck M. E., McClelland A. The major human rhinovirus receptor is ICAM-1. Cell. 56:1989;839-847.
16. Hong S. S., Boulanger P. Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage displayed peptide library on separate domains of wild-type and mutant penton capsomers. EMBO J. 14:1995;4714-4727.
17. Hong S. S., Karayan L., Tournier J., Curiel D. T., Boulanger P. A. Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 16:1997;2294-2306.
18. Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45:1989;381-416.
19. Huber S. A., Job L. P., Auld K. R. Influence of sex hormones on coxsackie B-3 virus infection in balb/c mice. Cell. Immunol. 67:1982;173-189.
20. Kandolf R., Hofschneider P. H. Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: Full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc. Natl. Acad. Sci. USA. 82:1985;4818-4822.
21. Kandolf R., Klingel K., Zell R., Canu A., Fortmuller U., Hohenadl C., Albrecht M., Reimann B.-Y., Franz W. M., Heim A., Raab U., McPhee F. Molecular mechanisms in the pathogenesis of enteroviral heart disease: Acute and persistent infections. Clin. Immunol. Immunopathol. 68:1993;153-158.
22. Klingel K., Hohenadl C., Canu A., Albrecht M., Seemann M., Mall G., Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: Quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl. Acad. Sci. USA. 89:1992;314-318.
23. Klump W. M., Bergmann I., Muller B. C., Ameis D., Kandolf R. Complete nucleotide sequence of infectious coxsackievirus B3 cDNA: Two initial 5′ uridine residues are regained during plus-strand RNA synthesis. J. Virol. 64:1990;1573-1583.
24. Liu P., Martino T., Opavsky A., Penninger J. Viral myocarditis: Balance between viral infection and immune response. Can. J. Cardiol. 12:1996;935-943.
25. Lonberg-Holm K., Crowell R. L., Philipson L. Unrelated animal viruses share receptors. Nature (London). 259:1976;679-681.
26. Lublin D. M., Atkinson J. P. Decay-accelerating factor: Biochemistry, molecular biology, and function. Ann. Rev. Immunol. 7:1989;35-58.
27. Martino T. A., Aitken K., Chow L., Gauntt C., Bartosik L., Bugeja A., Weinrib L., Ko J., Martino J., Shin M., Sole M., Petric M., Liu P. Identification of Capsid Mutations in Common Myocarditic Strains of Coxsackievirus B3 by Nucleotide Sequencing: Implications for Virus-Receptor,-Immune, and -Autoimmune Interactions. 1997.
28. Martino T. A., Aitken K., Penninger J., Mak T., Sole M. J., Dawood F., Wen W. H., Liu P. Mice with p56lck T-lymphocyte tyrosine kinase knocked our are resistant to coxsackieviral myocarditis. Can. J. Cardiol. 11:1995a;78E.
29. Martino T. A., Liu P., Petric M., Sole M. J. Enteroviral myocarditis and dilated cardiomyopathy: A review of clinical and experimental studies. Rotbart H. A. Human Enterovirus Infections. 1995b;291-351 Am. Soc. for Microbiol. Washington.
30. Martino T. A., Liu P., Sole M. J. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74:1995c;182-188.
31. Martino T. A., Liu P., Sole M. J. Viral infection and the pathogenesis of dilated cardiomyopathy: Time to revisit the virus. Heart Failure. 9:1994;182-188.
32. Mason J. W., O'Connell J. B., Herskowitz A., Rose N. R., McManus B. M., Billingham M. E., Moon T. E. A clinical trial of immunosuppressive therapy for myocarditis. N. Engl. J. Med. 333:1995;269-313.
33. Medof M. E., Walter E. I., Roberts W. L., Haas R., Rosenberry T. L. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid. Biochemistry. 25:1986;6740-6747.
34. Nicholson-Weller A., Wang C. E. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123:1994;485-491.
35. Raab de Verdugo U., Selinka H.-C., Huber M., Kramer B., Kellermann J., Hofschneider P. H., Kandolf R. Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses. J. Virol. 69:1995;6751-6757.
36. Reagan K. J., Goldberg B., Crowell R. L. Altered receptor specificity of coxsackie B3 after growth in rhabdomyosarcoma cells. J. Virol. 49:1984;635-640.
37. Shafren D. R., Bates R. C., Agrez M. V., Herd R. L., Burns G. F., Barry R. D. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J. Virol. 69:1995;3873-3877.
38. Shafren D. R., Dorahy D. J., Greive S. J., Burns G. F., Barry R. D. Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J. Virol. 71:1997a;785-789.
39. Shafren D. R., Dorahy D. J., Ingham R. A., Burns G. F., Barry R. D. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J. Virol. 71:1997b;4736-4743.
40. lckfyn. J. Immunol. 149:1992;3535-3541.
41. Song W. C., Deng C., Raszmann K., Moore R., Newbold R., McLachlan J. A., Negishi M. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J. Immunol. 157:1996;4166-4172.
42. Spicer A. P., Seldin M. F., Gendler S. J. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J. Immunol. 155:1995;3079-3091.
43. Stauton D. E., Merluzzi V. J., Rothlein R., Barton R., Marlin S. D., Springer T. A. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell. 56:1989;849-853.
44. Tomassini J. E., Graham D., DeWitt C. M., Lineberger D. W., Rodkey J. A., Colonno R. J. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA. 86:1989;4907-4911.
45. Tomko P. R., Xu R., Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA. 94:1997;3352-3356.
46. Tracy S., Chapman N. M., Tu Z. Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice. Arch. Virol. 122:1992;399-409.
47. Tu Z., Chapman N. M., Hufnagel G., Tracy S., Romero J. R., Barry W. H., Zhao L., Currey K., Shapiro B. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J. Virol. 69:1995;4607-4618.
48. Van Houten N., Bouchard P. E., Morasha A., Huber S. A. Selection of an attenuated coxsackie virus B3 variant using a monoclonal antibody reactive to myocyte antigen. J. Virol. 65:1991;1286-1290.
49. Br. Heart J. 44:1980;672-673.
50. v3v5. Cell. 73:1993;309-319.
51. Wilson F. M., Miranda Q. R., Chason J. L., Lerner A. M. Residual pathologic changes following murine coxsackie A and B myocarditis. Am. J. Pathol. 55:1969;253-265.
52. Woodruff J. F. Viral myocarditis: A review. Am. J. Pathol. 101:1980;425-484.
53. Zajac H., Crowell R. L. Differential inhibition of attachment and eclipse activities of HeLa cells for enteroviruses. J. Virol. 3:1969;422-428.